NMRA vs. DYN, IMCR, EVO, VIR, GPCR, TVTX, SDGR, XNCR, NRIX, and ARDX
Should you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), Vir Biotechnology (VIR), Structure Therapeutics (GPCR), Travere Therapeutics (TVTX), Schrödinger (SDGR), Xencor (XNCR), Nurix Therapeutics (NRIX), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.
Neumora Therapeutics vs.
Dyne Therapeutics (NASDAQ:DYN) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.
Dyne Therapeutics' return on equity of -57.46% beat Neumora Therapeutics' return on equity.
Dyne Therapeutics received 11 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 89.29% of users gave Neumora Therapeutics an outperform vote while only 75.00% of users gave Dyne Therapeutics an outperform vote.
Dyne Therapeutics currently has a consensus price target of $49.91, indicating a potential upside of 253.21%. Neumora Therapeutics has a consensus price target of $16.50, indicating a potential upside of 704.88%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Dyne Therapeutics.
In the previous week, Dyne Therapeutics had 2 more articles in the media than Neumora Therapeutics. MarketBeat recorded 6 mentions for Dyne Therapeutics and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.06 beat Dyne Therapeutics' score of 0.02 indicating that Neumora Therapeutics is being referred to more favorably in the news media.
Dyne Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.
96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 26.4% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Dyne Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500.
Summary
Dyne Therapeutics and Neumora Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Neumora Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neumora Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NMRA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free NMRA Stock Alerts